Adana

Running trials

• Recruiting

  Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

  NCT07711002· Phase 3· Source

• Recruiting

  A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

  NCT07761117· Phase 3· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

  NCT07662135· Phase 3· Source

• Recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

  NCT07662044· Phase 3· Source

• Recruiting

  A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

  NCT07667803· Phase 3· Source

• Recruiting

  A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

  NCT07606066· Source

• Active, not recruiting

  A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

  NCT07222917· Phase 2· Source

• Recruiting

  A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

  NCT07082738· Phase 2· Source

• Active, not recruiting

  A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

  NCT07000136· Phase 3· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

  NCT06878261· Phase 3· Source

• Recruiting

  A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

  NCT06742723· Phase 3· Source

• Recruiting

  Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  NCT06307652· Phase 3· Source

• Active, not recruiting

  A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

  NCT06268873· Phase 3· Source

• Recruiting

  A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

  NCT06283966· Phase 3· Source

• Recruiting

  Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

  NCT06079671· Phase 3· Source

• Active, not recruiting

  Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

  NCT05687266· Phase 3· Source

• Active, not recruiting

  Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

  NCT05261399· Phase 3· Source

• Active, not recruiting

  Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT05348577· Phase 3· Source

• Active, not recruiting

  Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

  NCT05043090· Phase 3· Source

• Active, not recruiting

  Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

  NCT04960709· Phase 3· Source

• Active, not recruiting

  D9319C00001- 1L OC Mono Global RCT

  NCT04884360· Phase 3· Source

• Active, not recruiting

  Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

  NCT04784715· Phase 3· Source

• Active, not recruiting

  Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT04612751· Phase 1· Source

• Active, not recruiting

  A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

  NCT04711252· Phase 3· Source

• Active, not recruiting

  Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients

  NCT03737643· Phase 3· Source

• Active, not recruiting

  A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

  NCT03706690· Phase 3· Source

• Active, not recruiting

  Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

  NCT03732820· Phase 3· Source

• Active, not recruiting

  Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

  NCT03682068· Phase 3· Source

• Active, not recruiting

  Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT03703297· Phase 3· Source

• Active, not recruiting

  A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

  NCT03521154· Phase 3· Source

• Active, not recruiting

  Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

  NCT02542293· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Type 2 diabetes4 recruiting
• COPD3 recruiting
• Chronic kidney disease2 recruiting
• Heart failure2 recruiting
• Cervical cancer1 recruiting
• Childhood cancers1 recruiting
• High blood pressure1 recruiting
• Obesity1 recruiting
• Prostate cancer1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations

  NCT06529419· Phase 2· Source

• Completed

  A Study to Investigate the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants With Resistant Hypertension

  NCT06168409· Phase 3· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension

  NCT06034743· Phase 3· Source

• Completed

  Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

  NCT06040086· Phase 3· Source

• Completed

  A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

  NCT05809934· Phase 2· Source

• Completed

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· Phase 3· Source

• Completed

  An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

  NCT05492877· Phase 2· Source

• Completed

  Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

  NCT04609904· Phase 3· Source

• Completed

  Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

  NCT04736173· Phase 2· Source

• Completed

  Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

  NCT04642469· Phase 3· Source

• Completed

  Durvalumab Long-Term Safety and Efficacy Study

  NCT04078152· Phase 4· Source

• Completed

  Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

  NCT04053634· Phase 3· Source

• Completed

  Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

  NCT02000622· Phase 3· Source